Cargando…
The co-delivery of a low-dose P-glycoprotein inhibitor with doxorubicin sterically stabilized liposomes against breast cancer with low P-glycoprotein expression
INTRODUCTION: P-glycoprotein (P-gp) inhibitors are usually used to treat tumors that overexpress P-gps. However, most common types of breast cancers, such as Luminal A, are low-P-gp expressing, at least during the initial phases of treatment. Therefore, it would be interesting to know if P-gp inhibi...
Autores principales: | Gao, Wei, Lin, Zhiqiang, Chen, Meiwan, Yang, Xiucong, Cui, Zheng, Zhang, Xiaofei, Yuan, Lan, Zhang, Qiang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4113405/ https://www.ncbi.nlm.nih.gov/pubmed/25092974 http://dx.doi.org/10.2147/IJN.S56070 |
Ejemplares similares
-
Evodiamine Synergizes with Doxorubicin in the Treatment of Chemoresistant Human Breast Cancer without Inhibiting P-Glycoprotein
por: Wang, Shengpeng, et al.
Publicado: (2014) -
Reconstitution and functional studies of hamster P-glycoprotein in giant liposomes
por: Park, SooHyun, et al.
Publicado: (2018) -
Pleiotrophin promotes chemoresistance to doxorubicin in osteosarcoma by upregulating P-glycoprotein
por: Wu, Dapeng, et al.
Publicado: (2017) -
Potentiation of Low-Dose Doxorubicin Cytotoxicity by Affecting P-Glycoprotein through Caryophyllane Sesquiterpenes in HepG2 Cells: An In Vitro and In Silico Study
por: Di Sotto, Antonella, et al.
Publicado: (2020) -
P-glycoprotein Inhibition for Optimal Drug Delivery
por: Amin, Md. Lutful
Publicado: (2013)